[1] van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003 Nov 1;57(3):205-25. doi: 10.1002/pros.10290. PMID: 14518029.
[2] Chrisofos M, Papatsoris AG, Lazaris A, Deliveliotis C. Precursor lesions of prostate cancer. Crit Rev Clin Lab Sci. 2007;44(3):243-70. doi: 10.1080/10408360601177236. PMID: 17453919.
[3] Yassin A, AlRumaihi K, Alzubaidi R, Alkadhi S, Al Ansari A. Testosterone, testosterone therapy and prostate cancer. Aging Male. 2019 Dec;22(4):219-227. doi: 10.1080/13685538.2018.1524456. Epub 2019 Jan 7. PMID: 30614347.
[4] Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, Cook J, Davidson R, Donaldson A, Eason J, Gregory H, Henderson A, Izatt L, Kennedy MJ, Miller C, Morrison PJ, Murray A, Ong KR, Porteous M, Pottinger C, Rogers MT, Side L, Snape K, Walker L, Tischkowitz M, Eeles R, Easton DF, Antoniou AC. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol. 2020 Jan;77(1):24-35. doi: 10.1016/j.eururo.2019.08.025. Epub 2019 Sep 6. PMID: 31495749; PMCID: PMC6926480.